Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T18:52:45.677Z.
Calculation as of: 2026-10-06T18:52:45.677Z.
Quote observation: 2026-10-06T18:45:36.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: fd4e67db9f72c8f7e350226876d0b852307266b6ff0bede5899e1be1bde0c950
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Polaryx Therapeutics, Inc. Common Stock
Market Cap
$103.73M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$104.00M
EV/Sales Ratio
N/A
TTM Avg
1.96x
3Y Avg
1.96x
5Y Avg
1.96x
Market Cap
$104.28M
EV/Sales Ratio
N/A
TTM Avg
501.64x
3Y Avg
356.48x
5Y Avg
292.72x
Market Cap
$104.82M
EV/Sales Ratio
0.43x
TTM Avg
0.80x
3Y Avg
2.27x
5Y Avg
5.02x
Market Cap
$107.09M
EV/Sales Ratio
N/A
TTM Avg
86.52x
3Y Avg
45.27x
5Y Avg
201.32x
Market Cap
$108.03M
EV/Sales Ratio
N/A
TTM Avg
103.10x
3Y Avg
102.99x
5Y Avg
102.99x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Polaryx Therapeutics, Inc. Common Stock (PLYX) | $103.73M | N/A | N/A | N/A | N/A |
| Black Diamond Therapeutics, Inc. (BDTX)vs › | $104.00M | N/A | 1.96x | 1.96x | 1.96x |
| Anixa Biosciences, Inc. (ANIX)vs › | $104.28M | N/A | 501.64x | 356.48x | 292.72x |
| The Joint Corp. (JYNT)vs › | $102.67M | 1.41x | 27.18x | 11.41x | 8.91x |
| Definitive Healthcare Corp. (DH)vs › | $104.82M | 0.43x | 0.80x | 2.27x | 5.02x |
| OnKure Therapeutics, Inc. (OKUR)vs › | $102.05M | N/A | N/A | N/A | N/A |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP)vs › | $107.09M | N/A | 86.52x | 45.27x | 201.32x |
| Immunic, Inc. (IMUX)vs › | $107.06M | N/A | N/A | N/A | N/A |
| Outlook Therapeutics, Inc. (OTLK)vs › | $108.03M | N/A | 103.10x | 102.99x | 102.99x |
| Cumberland Pharmaceuticals Inc. (CPIX)vs › | $109.23M | 3.52x | 1.78x | 1.24x | 1.09x |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
